Atrogi

Early findings support phase 2 plans for 2027

In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combi...

In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combination with a beneficial effect on body composition, with an increase in lean muscle mass and a reduction in

Flerie AB's (publ) portfolio company Atrogi has reported positive results from a clinical proof-of-mechanism study of its lead candidate ATR-258, a first-in-class, once-daily oral therapy designed to improve

Atrogi AB, a clinical stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces that the first subjects have been dosed in a human trial for its lead candidate, ATR-258, evaluating

First-in-class oral therapy ATR-258 mimics the effects of exercise - driving fat loss, increasing muscle, and improving metabolism - with broad potential as a...